Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton's Tyrosine Kinase.

Ong LL, Vasta JD, Monereau L, Locke G, Ribeiro H, Pattoli MA, Skala S, Burke JR, Watterson SH, Tino JA, Meisenheimer PL, Arey B, Lippy J, Zhang L, Robers MB, Tebben A, Chaudhry C.

SLAS Discov. 2019 Nov 9:2472555219884881. doi: 10.1177/2472555219884881. [Epub ahead of print]

PMID:
31709883
2.

Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile.

Simon CT, Skala SL, Killen PD, Siddiqui J, Cao X, Qiao Y, Al-Ahmadie H, Camelo-Piragua SI, Jentzen J, Chinnaiyan AM, Dhanasekaran SM, Reichert ZR, Mehra R.

Diagn Pathol. 2019 Oct 21;14(1):113. doi: 10.1186/s13000-019-0896-z.

3.

Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma.

Skala SL, Ye JC, Stumph J, Macon WR, Quinones FR, Khachaturov V, Ketterling RP, Dewar R.

Clin Pathol. 2019 Sep 29;12:2632010X19878410. doi: 10.1177/2632010X19878410. eCollection 2019 Jan-Dec.

4.

TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.

Gupta S, Argani P, Jungbluth AA, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Sanchez A, Hakimi AA, Mcfarlane T, Salazar PA, Williamson SR, Skala SL, Mehra R, Hes O, Antonescu CR, Ladanyi M, Arcila ME, Reuter VE.

Am J Surg Pathol. 2019 Nov;43(11):1445-1461. doi: 10.1097/PAS.0000000000001307.

PMID:
31600176
5.

Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation.

Skala SL, Gregg PA, Orr JW Jr, Udager AM, Brown NA, Cho KR.

Int J Gynecol Pathol. 2019 Jul 18. doi: 10.1097/PGP.0000000000000627. [Epub ahead of print]

PMID:
31335448
6.

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).

Watterson SH, Liu Q, Beaudoin Bertrand M, Batt DG, Li L, Pattoli MA, Skala S, Cheng L, Obermeier MT, Moore R, Yang Z, Vickery R, Elzinga PA, Discenza L, D'Arienzo C, Gillooly KM, Taylor TL, Pulicicchio C, Zhang Y, Heimrich E, McIntyre KW, Ruan Q, Westhouse RA, Catlett IM, Zheng N, Chaudhry C, Dai J, Galella MA, Tebben AJ, Pokross M, Li J, Zhao R, Smith D, Rampulla R, Allentoff A, Wallace MA, Mathur A, Salter-Cid L, Macor JE, Carter PH, Fura A, Burke JR, Tino JA.

J Med Chem. 2019 Apr 11;62(7):3228-3250. doi: 10.1021/acs.jmedchem.9b00167. Epub 2019 Mar 29.

PMID:
30893553
7.

The utility of upper urinary tract urine cytology before and after application of the Paris system.

Simon CT, Skala SL, Magers MJ, Weizer A, Kaffenberger SD, Chinnaiyan AM, Spratt DE, Montgomery J, Mehra R, Lew M.

Diagn Cytopathol. 2019 May;47(5):421-427. doi: 10.1002/dc.24127. Epub 2018 Dec 19.

PMID:
30569543
8.

Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.

Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R.

Hum Pathol. 2019 Apr;86:76-84. doi: 10.1016/j.humpath.2018.11.021. Epub 2018 Dec 8.

PMID:
30537495
9.

Histiocytic Sarcoma: Review, Discussion of Transformation From B-Cell Lymphoma, and Differential Diagnosis.

Skala SL, Lucas DR, Dewar R.

Arch Pathol Lab Med. 2018 Nov;142(11):1322-1329. doi: 10.5858/arpa.2018-0220-RA. Review.

PMID:
30407858
10.

Primary Cutaneous Follicle Center Lymphoma.

Skala SL, Hristov B, Hristov AC.

Arch Pathol Lab Med. 2018 Nov;142(11):1313-1321. doi: 10.5858/arpa.2018-0215-RA. Review.

PMID:
30407851
11.

VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney.

Wang L, Zhang Y, Chen YB, Skala SL, Al-Ahmadie HA, Wang X, Cao X, Veeneman BA, Chen J, Cieślik M, Qiao Y, Su F, Vats P, Siddiqui J, Xiao H, Sadimin ET, Epstein JI, Zhou M, Sangoi AR, Trpkov K, Osunkoya AO, Giannico GA, McKenney JK, Argani P, Tickoo SK, Reuter VE, Chinnaiyan AM, Dhanasekaran SM, Mehra R.

Am J Surg Pathol. 2018 Dec;42(12):1571-1584. doi: 10.1097/PAS.0000000000001150.

PMID:
30285995
12.

Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma.

Skala SL, Dhanasekaran SM, Mehra R.

Arch Pathol Lab Med. 2018 Oct;142(10):1202-1215. doi: 10.5858/arpa.2018-0216-RA. Review.

PMID:
30281371
13.

CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.

McMullen ER, Gonzalez ME, Skala SL, Tran M, Thomas D, Djomehri SI, Burman B, Kidwell KM, Kleer CG.

Breast Cancer Res Treat. 2018 Dec;172(3):577-586. doi: 10.1007/s10549-018-4960-2. Epub 2018 Sep 15.

14.

Unsuspected lymphomatoid granulomatosis in a patient with antisynthetase syndrome.

Skala SL, Hristov AC, Gudjonsson JE, Chan MP.

Cutis. 2017 Oct;100(4):E22-E26.

PMID:
29136066
15.

Comprehensive histopathological comparison of epidermotropic/dermal metastatic melanoma and primary nodular melanoma.

Skala SL, Arps DP, Zhao L, Cha KB, Wang M, Harms PW, Andea AA, Fullen DR, Chan MP.

Histopathology. 2018 Feb;72(3):472-480. doi: 10.1111/his.13384. Epub 2017 Nov 21.

16.

Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, Landau C, Shao L, Roulston D, Wang L, Siddiqui J, Cao X, Magi-Galluzzi C, Zhang M, Osunkoya AO, Smith SC, McKenney JK, Betz BL, Myers JL, Chinnaiyan AM, Tomlins SA, Mehra R.

Mod Pathol. 2018 Jan;31(1):179-197. doi: 10.1038/modpathol.2017.99. Epub 2017 Aug 25.

17.

Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.

Skala SL, Liu TY, Udager AM, Weizer AZ, Montgomery JS, Palapattu GS, Siddiqui J, Cao X, Fields K, Abugharib AE, Soliman M, Hafez KS, Miller D, Lee CT, Alva A, Chinnaiyan AM, Morgan TM, Spratt DE, Jiang H, Mehra R.

Eur Urol Focus. 2017 Oct;3(4-5):502-509. doi: 10.1016/j.euf.2016.11.011. Epub 2016 Dec 13.

PMID:
28753826
18.

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.

Gillooly KM, Pulicicchio C, Pattoli MA, Cheng L, Skala S, Heimrich EM, McIntyre KW, Taylor TL, Kukral DW, Dudhgaonkar S, Nagar J, Banas D, Watterson SH, Tino JA, Fura A, Burke JR.

PLoS One. 2017 Jul 24;12(7):e0181782. doi: 10.1371/journal.pone.0181782. eCollection 2017.

19.

Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.

Liu Q, Shi Q, Marcoux D, Batt DG, Cornelius L, Qin LY, Ruan Z, Neels J, Beaudoin-Bertrand M, Srivastava AS, Li L, Cherney RJ, Gong H, Watterson SH, Weigelt C, Gillooly KM, McIntyre KW, Xie JH, Obermeier MT, Fura A, Sleczka B, Stefanski K, Fancher RM, Padmanabhan S, Rp T, Kundu I, Rajareddy K, Smith R, Hennan JK, Xing D, Fan J, Levesque PC, Ruan Q, Pitt S, Zhang R, Pedicord D, Pan J, Yarde M, Lu H, Lippy J, Goldstine C, Skala S, Rampulla RA, Mathur A, Gupta A, Arunachalam PN, Sack JS, Muckelbauer JK, Cvijic ME, Salter-Cid LM, Bhide RS, Poss MA, Hynes J, Carter PH, Macor JE, Ruepp S, Schieven GL, Tino JA.

J Med Chem. 2017 Jun 22;60(12):5193-5208. doi: 10.1021/acs.jmedchem.7b00618. Epub 2017 Jun 5.

PMID:
28541707
20.

Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes.

Carter CS, Skala SL, Chinnaiyan AM, McHugh JB, Siddiqui J, Cao X, Dhanasekaran SM, Fullen DR, Lagstein A, Chan MP, Mehra R.

Am J Surg Pathol. 2017 Jun;41(6):801-809. doi: 10.1097/PAS.0000000000000840.

21.

Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.

Qin LY, Ruan Z, Cherney RJ, Dhar TGM, Neels J, Weigelt CA, Sack JS, Srivastava AS, Cornelius LAM, Tino JA, Stefanski K, Gu X, Xie J, Susulic V, Yang X, Yarde-Chinn M, Skala S, Bosnius R, Goldstein C, Davies P, Ruepp S, Salter-Cid L, Bhide RS, Poss MA.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):855-861. doi: 10.1016/j.bmcl.2017.01.016. Epub 2017 Jan 10.

PMID:
28108251
22.

Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis - Value of Autopsy in a Case Report.

Skala SL, Owens SR, Xiao H, Bauman KA, Tomlins SA, Chinnaiyan AM, Shao L, Jentzen JM, Gordon D, Mehra R.

Urol Case Rep. 2016 Sep 23;9:37-40. doi: 10.1016/j.eucr.2016.08.004. eCollection 2016 Nov.

23.

Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.

Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, Beaudoin Bertrand M, Gong H, Dai J, Yip S, Li P, Sun D, Wu DR, Wang C, Zhang Y, Traeger SC, Pattoli MA, Skala S, Cheng L, Obermeier MT, Vickery R, Discenza LN, D'Arienzo CJ, Zhang Y, Heimrich E, Gillooly KM, Taylor TL, Pulicicchio C, McIntyre KW, Galella MA, Tebben AJ, Muckelbauer JK, Chang C, Rampulla R, Mathur A, Salter-Cid L, Barrish JC, Carter PH, Fura A, Burke JR, Tino JA.

J Med Chem. 2016 Oct 13;59(19):9173-9200. Epub 2016 Sep 19.

PMID:
27583770
24.

Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).

De Lucca GV, Shi Q, Liu Q, Batt DG, Beaudoin Bertrand M, Rampulla R, Mathur A, Discenza L, D'Arienzo C, Dai J, Obermeier M, Vickery R, Zhang Y, Yang Z, Marathe P, Tebben AJ, Muckelbauer JK, Chang CJ, Zhang H, Gillooly K, Taylor T, Pattoli MA, Skala S, Kukral DW, McIntyre KW, Salter-Cid L, Fura A, Burke JR, Barrish JC, Carter PH, Tino JA.

J Med Chem. 2016 Sep 8;59(17):7915-35. doi: 10.1021/acs.jmedchem.6b00722. Epub 2016 Aug 26.

PMID:
27531604
25.

Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors.

Bhide RS, Neels J, Qin LY, Ruan Z, Stachura S, Weigelt C, Sack JS, Stefanski K, Gu X, Xie JH, Goldstine CB, Skala S, Pedicord DL, Ruepp S, Dhar TG, Carter PH, Salter-Cid LM, Poss MA, Davies P.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4256-60. doi: 10.1016/j.bmcl.2016.07.047. Epub 2016 Jul 21.

PMID:
27476421
26.

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.

Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R.

Ann Oncol. 2016 Sep;27(9):1706-12. doi: 10.1093/annonc/mdw216. Epub 2016 May 23.

27.

Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity.

Mangan PR, Su LJ, Jenny V, Tatum AL, Picarillo C, Skala S, Ditto N, Lin Z, Yang X, Cotter PZ, Shuster DJ, Song Y, Borowski V, Thomas RL, Heimrich EM, Devaux B, Das Gupta R, Carvajal I, McIntyre KW, Xie J, Zhao Q, Struthers M, Salter-Cid LM.

J Pharmacol Exp Ther. 2015 Aug;354(2):152-65. doi: 10.1124/jpet.115.224246. Epub 2015 May 26.

PMID:
26015463
28.

Optimal sampling of grossly normal omentum in staging of gynecologic malignancies.

Skala SL, Hagemann IS.

Int J Gynecol Pathol. 2015 May;34(3):281-7. doi: 10.1097/PGP.0000000000000148.

PMID:
25760907
29.

Major lessons learned from a nationally-based community-academic partnership: addressing sibling adjustment to childhood cancer.

Long KA, Goldish M, Lown EA, Ostrowski NL, Alderfer MA, Marsland AL, Ring S, Skala S, Ewing LJ.

Fam Syst Health. 2015 Mar;33(1):61-7. doi: 10.1037/fsh0000084. Epub 2015 Jan 12.

PMID:
25581558
30.

Factors associated with screening for sexually transmitted infections.

Skala SL, Secura GM, Peipert JF.

Am J Obstet Gynecol. 2012 Apr;206(4):324.e1-6. doi: 10.1016/j.ajog.2012.02.020. Epub 2012 Feb 28.

31.

Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521).

Watterson SH, Xiao Z, Dodd DS, Tortolani DR, Vaccaro W, Potin D, Launay M, Stetsko DK, Skala S, Davis PM, Lee D, Yang X, McIntyre KW, Balimane P, Patel K, Yang Z, Marathe P, Kadiyala P, Tebben AJ, Sheriff S, Chang CY, Ziemba T, Zhang H, Chen BC, DelMonte AJ, Aranibar N, McKinnon M, Barrish JC, Suchard SJ, Murali Dhar TG.

J Med Chem. 2010 May 13;53(9):3814-30. doi: 10.1021/jm100348u.

PMID:
20405922
32.

An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis.

Suchard SJ, Stetsko DK, Davis PM, Skala S, Potin D, Launay M, Dhar TG, Barrish JC, Susulic V, Shuster DJ, McIntyre KW, McKinnon M, Salter-Cid L.

J Immunol. 2010 Apr 1;184(7):3917-26. doi: 10.4049/jimmunol.0901095. Epub 2010 Feb 26.

33.

Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101)--a small molecule antagonist of leukocyte function associated antigen-1.

Potin D, Launay M, Monatlik F, Malabre P, Fabreguettes M, Fouquet A, Maillet M, Nicolai E, Dorgeret L, Chevallier F, Besse D, Dufort M, Caussade F, Ahmad SZ, Stetsko DK, Skala S, Davis PM, Balimane P, Patel K, Yang Z, Marathe P, Postelneck J, Townsend RM, Goldfarb V, Sheriff S, Einspahr H, Kish K, Malley MF, DiMarco JD, Gougoutas JZ, Kadiyala P, Cheney DL, Tejwani RW, Murphy DK, Mcintyre KW, Yang X, Chao S, Leith L, Xiao Z, Mathur A, Chen BC, Wu DR, Traeger SC, McKinnon M, Barrish JC, Robl JA, Iwanowicz EJ, Suchard SJ, Dhar TG.

J Med Chem. 2006 Nov 30;49(24):6946-9.

PMID:
17125246
34.

De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold.

Potin D, Launay M, Nicolai E, Fabreguette M, Malabre P, Caussade F, Besse D, Skala S, Stetsko DK, Todderud G, Beno BR, Cheney DL, Chang CJ, Sheriff S, Hollenbaugh DL, Barrish JC, Iwanowicz EJ, Suchard SJ, Dhar TG.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1161-4.

PMID:
15686933
35.

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.

Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1487-90.

PMID:
12668018
36.

Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.

Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS.

Bioorg Med Chem Lett. 2002 Apr 22;12(8):1199-202.

PMID:
11934588
37.

The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.

Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS.

Bioorg Med Chem Lett. 2001 Nov 19;11(22):2975-8.

PMID:
11677139
38.

The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.

Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2189-92.

PMID:
11514167
39.

Relapse patterns among adolescents treated for chemical dependency.

Spear SF, Ciesla JR, Skala SY.

Subst Use Misuse. 1999 Nov;34(13):1795-815. Review.

PMID:
10540973
40.

Posttreatment services for chemically dependent adolescents.

Spear SF, Skala SY.

NIDA Res Monogr. 1995;156:341-64. Review. No abstract available.

PMID:
8594477
41.

Structure of GaAs(100)-c(8 x 2) determined by scanning tunneling microscopy.

Skala SL, Hubacek JS, Tucker JR, Lyding JW, Chou ST, Cheng K.

Phys Rev B Condens Matter. 1993 Sep 15;48(12):9138-9141. No abstract available.

PMID:
10007140
42.

Scanning tunneling microscopy of the charge-density wave in orthorhombic TaS3.

Gammie G, Hubacek JS, Skala SL, Brockenbrough RT, Tucker JR, Lyding JW.

Phys Rev B Condens Matter. 1989 Dec 15;40(17):11965-11968. No abstract available.

PMID:
9991813
43.

Scanning tunneling microscopy of NbSe3 and orthorhombic TaS3.

Gammie G, Hubacek JS, Skala SL, Brockenbrough RT, Tucker JR, Lyding JW.

Phys Rev B Condens Matter. 1989 Nov 15;40(14):9529-9532. No abstract available.

PMID:
9991470

Supplemental Content

Support Center